JP2020514277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514277A5 JP2020514277A5 JP2019534414A JP2019534414A JP2020514277A5 JP 2020514277 A5 JP2020514277 A5 JP 2020514277A5 JP 2019534414 A JP2019534414 A JP 2019534414A JP 2019534414 A JP2019534414 A JP 2019534414A JP 2020514277 A5 JP2020514277 A5 JP 2020514277A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence
- substantially similar
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 18
- 239000000427 antigen Substances 0.000 claims 17
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 17
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 10
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 10
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 10
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 9
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 9
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 6
- 102000048776 human CD274 Human genes 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 238000011374 additional therapy Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000022534 cell killing Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000003259 recombinant expression Methods 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438622P | 2016-12-23 | 2016-12-23 | |
| US62/438,622 | 2016-12-23 | ||
| PCT/US2017/068369 WO2018119475A1 (en) | 2016-12-23 | 2017-12-23 | Immunotherapy using antibodies that bind programmed death ligand-1 (pd-l1) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514277A JP2020514277A (ja) | 2020-05-21 |
| JP2020514277A5 true JP2020514277A5 (enExample) | 2021-02-04 |
| JP7128529B2 JP7128529B2 (ja) | 2022-08-31 |
Family
ID=62627185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534414A Active JP7128529B2 (ja) | 2016-12-23 | 2017-12-23 | プログラム死リガンド－１（ｐｄ－ｌ１）に結合する抗体を使用する免疫 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11332531B2 (enExample) |
| EP (1) | EP3559045A4 (enExample) |
| JP (1) | JP7128529B2 (enExample) |
| CN (1) | CN110337448B (enExample) |
| RU (1) | RU2766582C2 (enExample) |
| WO (1) | WO2018119475A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| AU2019241345A1 (en) * | 2018-03-29 | 2020-10-15 | Adagene Inc. | Anti-PD-L1 antibodies and use thereof |
| CA3130794A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| MX2022008925A (es) * | 2020-01-21 | 2022-10-18 | Bolt Biotherapeutics Inc | Anticuerpos anti-pd-l1. |
| CA3170330A1 (en) | 2020-02-21 | 2021-08-26 | Macrogenics, Inc. | Cd137 binding molecules and uses thereof |
| WO2021216832A1 (en) * | 2020-04-23 | 2021-10-28 | Remd Biotherapeutics, Inc. | Chemokine receptor 4 (cxcr4) antagonist antibodies |
| JP2024523838A (ja) * | 2021-06-09 | 2024-07-02 | シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド | Ｏｘ４０及び／又はｐｄ－ｌ１に結合する抗体及び二重特異性結合タンパク質 |
| CN118201953A (zh) * | 2021-08-18 | 2024-06-14 | 瑞美德生物医药科技有限公司 | 新型干扰素变体及其双功能融合分子 |
| TW202428607A (zh) * | 2022-12-19 | 2024-07-16 | 大陸商百奧賽圖(北京)醫藥科技股份有限公司 | 抗pdl1抗體及其用途 |
| JP2026504180A (ja) | 2023-01-30 | 2026-02-03 | カイマブ・リミテッド | 抗体 |
| CN117126282B (zh) * | 2023-10-26 | 2024-01-12 | 迈威(上海)生物科技股份有限公司 | 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100823764B1 (ko) * | 2000-06-22 | 2008-04-21 | 제넨테크, 인크. | 아고니스트 안티-티알케이-씨 모노클로날 항체 |
| US7514078B2 (en) * | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| EP1544291A4 (en) | 2002-07-19 | 2006-08-02 | Towa Kagaku Co Ltd | A NEW METHOD FOR THE PRODUCTION OF ANTIBODY CYME, NEW ANTIBODY CYM AND USE THEREOF |
| EA019344B1 (ru) * | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| KR100882445B1 (ko) * | 2007-03-16 | 2009-02-09 | 울산대학교 산학협력단 | 항―４－１ｂｂ 항체를 이용한 항원 특이적 자가유래ｃｄ８＋ｔ 세포의 분리 및 증식 방법 |
| CN101868246A (zh) | 2007-09-21 | 2010-10-20 | 加利福尼亚大学董事会 | 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性 |
| WO2010047830A2 (en) | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | Agents for hcv treatment |
| HUE065752T2 (hu) * | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| KR20110099762A (ko) * | 2008-12-26 | 2011-09-08 | 고쿠리츠다이가쿠호우진 도쿄다이가쿠 | 항ｌｇｒ７항체를 사용하는 암의 진단 및 치료 |
| WO2010109924A1 (ja) * | 2009-03-25 | 2010-09-30 | 国立大学法人東北大学 | Ｌｈ型二重特異性抗体 |
| JP2012034668A (ja) * | 2010-08-12 | 2012-02-23 | Tohoku Univ | ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用 |
| AR085091A1 (es) | 2011-01-26 | 2013-09-11 | Kolltan Pharmaceuticals Inc | Anticuerpos anti-kit y sus usos |
| JP6072771B2 (ja) * | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101981873B1 (ko) * | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| CA3175979A1 (en) * | 2014-12-22 | 2016-06-30 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
| AU2015380455A1 (en) * | 2015-01-26 | 2017-08-03 | Macrogenics, Inc. | Multivalent molecules comprising DR5-binding domains |
-
2017
- 2017-12-23 EP EP17883244.0A patent/EP3559045A4/en active Pending
- 2017-12-23 CN CN201780087354.6A patent/CN110337448B/zh active Active
- 2017-12-23 RU RU2019121086A patent/RU2766582C2/ru active
- 2017-12-23 JP JP2019534414A patent/JP7128529B2/ja active Active
- 2017-12-23 WO PCT/US2017/068369 patent/WO2018119475A1/en not_active Ceased
- 2017-12-23 US US16/472,724 patent/US11332531B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514277A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| TWI784976B (zh) | 抗ｌａｇ-３抗體及組成物 | |
| CN107922503B (zh) | 一种pdl-1抗体、其药物组合物及其用途 | |
| TW202126692A (zh) | 抗人Claudin18.2抗體及其應用 | |
| JP2022177090A5 (enExample) | ||
| JP2020513759A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2017149720A5 (enExample) | ||
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2020508655A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| HRP20200583T1 (hr) | Protutijela koja neutraliziraju gp120 i njihova upotreba | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| RU2018137110A (ru) | Антитела против psma и их применение | |
| RU2019121106A (ru) | Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1) | |
| JP2017521054A5 (enExample) | ||
| JP2024024114A5 (enExample) | ||
| JP2020502233A5 (enExample) | ||
| RU2019111862A (ru) | Новые антитела против фактора xi и их применения | |
| JP2019505477A5 (enExample) | ||
| RU2019125975A (ru) | Связывающие агенты | |
| RU2016141285A (ru) | Биспецифические антигенсвязывающие полипептиды |